148-18-5
148-18-5
Chemical Structure
Ditiocarb sodium
Synonym(s): Sodium diethyldithiocarbamate
- CAS No.: 148-18-5
- Formula:C5H10NNaS2
- Molecular Weight:171.26
IUPAC Name: sodium diethylcarbamodithioate
InChIKey: IOEJYZSZYUROLN-UHFFFAOYSA-M
SMILES: S=C(S[Na])N(CC)CC
Biological Activity: Ditiocarb sodium (Sodium diethyldithiocarbamate) is an orally active copper reagent. Ditiocarb sodium exhibits activities such as antioxidation, chelation, anti-tumor effects, immunomodulation, and anti-HIV properties. Ditiocarb sodium can be used in the research of tumors, inflammatory, and immune-related diseases[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ditiocarb sodium | 99.78% | Ditiocarb sodium (Sodium diethyldithiocarbamate) is an orally active copper reagent. Ditiocarb sodium exhibits activities such as antioxidation, chelation, anti-tumor effects, immunomodulation, and anti-HIV properties. Ditiocarb sodium can be used in the research of tumors, inflammatory, and immune-related diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ditiocarb sodium (Standard) | ≥98% | Ditiocarb sodium (Standard) is the analytical standard of Ditiocarb sodium. This product is intended for research and analytical applications. Ditiocarb sodium (Sodium diethyldithiocarbamate) is a copper reagent. The reaction with Cu2+ solution resulted in the formation of a complex, which increased the copper displacement precipitation rate. Ditiocarb sodium can reduce HIV infection and can be used in adjuvant immune research of high-risk breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ditiocarb sodium,98% | 99.2% | Ditiocarb sodium,98% (Sodium diethyldithiocarbamate,98%) is an orally active copper reagent. Ditiocarb sodium,98% exhibits activities such as antioxidation, chelation, anti-tumor effects, immunomodulation, and anti-HIV properties. Ditiocarb sodium,98% can be used in the research of tumors, inflammatory, and immune-related diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ditiocarb-d10 sodium | Ditiocarb-d10 sodium (Sodium diethyldithiocarbamate-d10) is the deuterium labeled Ditiocarb sodium (HY-B1637). Ditiocarb sodium (Sodium diethyldithiocarbamate) is an orally active copper reagent. Ditiocarb sodium exhibits activities such as antioxidation, chelation, anti-tumor effects, immunomodulation, and anti-HIV properties. Ditiocarb sodium can be used in the research of tumors, inflammatory, and immune-related diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.91
HY-W009722Sodium diethylcarbamodithioate trihydrate -
Similarity Score 0.86
HY-W034674Silver diethyldithiocarbamate -
Similarity Score 0.86
HY-151229S-Methyl-N,N-diethylthiolcarbamate -
Similarity Score 0.82
HY-126363Ditiocarb -
Similarity Score 0.78
HY-143850SMethyl diethyldithiocarbamate-d3 -
Similarity Score 0.74
HY-W008829N,N-Diethylacetamide -
Similarity Score 0.72
HY-121817Sulfiram -
Similarity Score 0.70
HY-W051299Diethylglycine -
Similarity Score 0.69
HY-186038Cyanoethyl dimethyldithiocarbamate -
Explore the MedChemAI to find more analogs
References
- [1]. Abeer A.El-Saharty, et al. Sodium diethyldithiocarbamate as accelerator of the rate of copper cementation. The Egyptian Journal of Aquatic Research. 2015 Dec, Volume 41(4):289-293.
- [2]. Hersh EM, et al. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study. JAMA. 1991 Mar 27;265(12):1538-44. [Content Brief]
- [3]. Borch RF, et al. Inhibition of cis-platinum nephrotoxicity by diethyldithiocarbamate rescue in a rat model. Proc Natl Acad Sci U S A. 1979 Dec;76(12):6611-4. [Content Brief]
- [4]. Perchellet JP, et al. Inhibition of multistage tumor promotion in mouse skin by diethyldithiocarbamate. Cancer Res. 1987 Dec 1;47(23):6302-9. [Content Brief]
